# First in Human Trial to Assess the Feasibility and Preliminary Safety of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill Patients with Sepsis-induced Immunosuppression

> **NCT06258291** · NA · NOT_YET_RECRUITING · sponsor: **hemotune AG** · enrollment: 16 (estimated)

## Conditions studied

- Septic Shock

## Interventions

- **DEVICE:** Hemosystem REBOOT

## Key facts

- **NCT ID:** NCT06258291
- **Lead sponsor:** hemotune AG
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-07-28
- **Final completion:** 2026-12-30
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06258291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06258291, "First in Human Trial to Assess the Feasibility and Preliminary Safety of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill Patients with Sepsis-induced Immunosuppression". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06258291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*